ChromaCode, Inc.

ChromaCode, Inc. is a US-based company specializing in advanced genomic testing through its proprietary multiplexing technology, enhancing the efficiency and accuracy of DNA and RNA analysis. Founded in 2012 and headquartered in Carlsbad, US, ChromaCode, Inc. is focused on developing advanced genomic testing solutions.

The company has not undergone any significant changes in business strategy. The founders include Aditya Rajagopal and Alex Dickinson, while Mark McDonough serves as the CEO. ChromaCode raised a total of USD 10. 00 mn in its most recent funding round, Series D, on February 27, 2023, with participation from investors such as Adjuvant Capital, California Institute of Technology Endowment, and others.

The company has completed 9 funding deals overall, with a total amount raised of USD 10. 00 mn and a current valuation of USD 127. 455 mn. ChromaCode specializes in its proprietary High-Definition PCR (HDPCR™) multiplexing technology, which enhances genomic testing capabilities by allowing for the simultaneous analysis of multiple DNA and RNA targets.

This innovative platform is designed to deliver rapid, cost-effective solutions for oncology and genomic applications, enabling healthcare providers and laboratories to achieve faster turnaround times and improved decision-making. The HDPCR technology facilitates comprehensive tumor profiling and minimal residual disease (MRD) testing, addressing a significant need in patient management by providing access to critical biomarkers. Targeted primarily at laboratories, hospitals, and medical research institutions, ChromaCode aims to revolutionize genomic testing workflows and is positioned to serve markets in the United States and globally, reaching millions of patients who could benefit from their advanced diagnostic capabilities. ChromaCode's revenue model is structured around partnerships and direct sales to healthcare providers and laboratories, leveraging its HDPCR technology to enhance their service offerings.

The company generates revenue through the sale of reagent kits and access to its cloud-based software, which facilitates data analysis and interpretation of genomic test results. Clients typically engage in B2B transactions, where laboratories purchase these kits to perform advanced genomic assays in their facilities. While specific pricing details for individual products and services are not disclosed, the HDPCR system is noted for its high margins and cost-effective workflows which are advantageous for lab partners. This revenue structure supports ChromaCode's mission to expand the availability of personalized genomic testing, thereby improving health outcomes and offering significant value to its customers in the oncology and genomics sectors.

In February 2023, ChromaCode, Inc. raised USD 10. 00 mn in Series D funding to support the development of its cancer and infectious diseases testing technologies. The company plans to utilize this funding to enhance its product offerings and expand its market reach.

Future product launches are anticipated, although specific new products and release dates have not been disclosed. ChromaCode is focused on expanding its presence in both U. S. and global markets, aiming to improve accessibility to genomic testing technologies for a wider range of healthcare providers.